Related news and resources
158th session of the WHO Executive Board: Substandard and falsified medical products
On 4 February 2026, IAPO delivered a statement on Agenda item 12 on substandard and falsified medical products at the 158th session of the WHO Executive Board on behalf of the Fight the Fakes Alliance, of which IFPMA is a member. The International Alliance of Patients’ Organizations, on behalf of the Fight the Fakes Alliance,...
Read moreThe role of assessment reports in enabling regulatory reliance – perspectives from the pharmaceutical industry
Reliance in decision-making offers a pathway for national regulatory authorities (NRAs) to consider evaluations conducted by other NRAs while maintaining accountability for their decisions. By avoiding duplicative reviews and optimizing resource allocation, the use of regulatory reliance can lead to faster patient access to safe, effective, and high-quality medical products in a timely manner. A...
Read more
Best practices for unilateral reliance for initial marketing authorization and post-approval changes
Regulatory reliance has emerged as a key strategy for strengthening regulatory systems by optimizing resources, reducing duplication, and accelerating access to high-quality medicines. By leveraging the expertise and prior decisions of trusted national regulatory authorities (NRAs), reliance allows NRAs to focus their efforts on critical public health priorities while maintaining sovereignty over final regulatory decisions....
Read more